Journal of Practical Hepatology ›› 2024, Vol. 27 ›› Issue (1): 11-15.doi: 10.3969/j.issn.1672-5069.2024.01.004
Previous Articles Next Articles
Zhang Ming
Received:
2023-11-09
Online:
2024-01-10
Published:
2024-01-04
Zhang Ming. Portal vein thrombosis in cirrhotic patients: the states of the art[J]. Journal of Practical Hepatology, 2024, 27(1): 11-15.
[1] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海).中华消化杂志, 2020,40(11) : 721-730. [2] Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021,75(2):442-453. [3] Molvar C, Amin P. Portal vein thrombosis in cirrhosis: Interventional treatment options. Curr Gastroenterol Rep,2021,23(12):24. [4] Pan J, Wang L, Gao F,et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med, 2022,104:21-32. [5] Shukla A, Giri S. Portal vein thrombosis in cirrhosis. J ClinExp Hepatol,2022 12(3):965-979. [6] Anton A, Campreciós G, Pérez-Campuzano V,et al. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow's triad. J Clin Med,2022,11(3):800. [7] Stine JG, Wang J, Shah PM,et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int, 2018,38(1):94-101. [8] Intagliata NM, Argo CK, Stine JG, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th international coagulation in liver disease conference. Thromb Haemost,2018, 118(8):1491-1506. [9] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosisconsist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology, 2022,75:898–911. [10] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost, 2020,46(6):673-681. [11] Ghabril M, Agarwal S, Lacerda M,et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: Analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients. Transplantation, 2016,100(1):126-33. [12] Qi X, Dai J, Jia J,et al. Association between portal vein thrombosis and survival of liver transplant recipients: a systematic review and meta-analysis of observational studies. J Gastrointestin Liver Dis,2015,24(1):51-59. [13] Basaranoglu M. Increased prevalence of portal vein thrombosis in patients with nonalcoholic steatohepatitis-cirrhosis due to increased proinflammatory cytokines releasing from abdominal adipose tissue. Eur J Gastroenterol Hepatol,2020,32(3):458. [14] Cagin YF, Bilgic Y, Berber , et al. The risk factors of portal vein thrombosis in patients with liver cirrhosis. Exp Ther Med,2019,17(4):3189-3194.. [15] Xu X, Guo X, De Stefano V,et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13(4):468-481. [16] Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: A challenging consequence of liver cirrhosis. J Clin Transl Hepatol,2020,8(4):432-444. [17] Turon F, Driever EG, Baiges A,et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol, 2021,75(6):1367-1376. [18] Sarin SK, Philips CA, Kamath PS, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology, 2016,151(4):574-577,e3. [19] Yerdel MA, Gunson B, Mirza D,et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation,2000,69(9):1873-1881. [20] Bhangui P, Lim C, Levesque E,et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. J Hepatol, 2019, 71(5):1038-1050. [21] Sherman CB, Behr S, Dodge JL,et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transpl,2019,25(2):207-216. [22] Seedial SM, Mouli SK, Desai KR. Acute portal vein thrombosis: Current trends in medical and endovascular management. Semin Intervent Radiol, 2018,35(3):198-202. [23] Itare VB, Imanirad D, Almaghraby A. Portal cholangiopathy: An uncommon cause of right upper quadrant pain. Cureus, 2020,12(9):e10281. [24] Rajesh S, Singh S, Philips CA. Transjugular intrahepatic portosystemic shunt in chronic portal vein thrombosis-From routine recommendations to demanding scenarios. Diagnostics (Basel),2022, 12(12):3100. [25] Yao C, Zhao M, Ibrahim B,et al. Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: A systematic review and Meta-analysis of comparative studies. J Clin Exp Hepatol, 2023, 13(3):404-413. [26] Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc,2020,9(13):e017559. [27] O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology, 2021,161:1615–1627,e1. [28] EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol, 2022,76:1151–1184. [29] Loffredo L, Pastori D, Farcomeni A,et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis. Gastroenterology, 2017,153(2):480-487,e1. [30] Koh JH, Liew ZH, Ng GK,et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis,2022,54(1):56-62. [31] Northup PG, Garcia-Pagan JC, Garcia-Tsao G,et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,73(1):366-413. [32] Sun XY, Wang GC, Wang J,et al. Transjugular intrahepatic portosystemic shunt is effective in patients with chronic portal vein thrombosis and variceal bleeding. Hepatobiliary Pancreat Dis Int,2021,20(2):128-136. [33] Lyu Y, Qi X, He C,et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut,2018,67(12):2156-2168. [34] Luo X, Wang Z, Tsauo J,et al. Advanced cirrhosis combined with portal vein thrombosis: A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology, 2015,276(1):286-293. [35] Jiang TT, Luo XP, Sun JM,et al. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis. World J Gastroenterol,2017,23(41):7470-7477. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||